Расширение группы препаратов, основанных на действии инкретинов: новый ингибитор ДПП-4 саксаглиптин
Аннотация
Список литературы
1. Deacon C.F., Carr R.D., Holst J.J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci 2008;13:1780-1794.
2. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157.
3. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439.
4. Holst J.J., Vilsboll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-136.
5. Vilsboll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357-366.
6. Nauck M.A., Kleine N., Orskov C. et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744.
7. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like pep-tide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997;40:205-211.
8. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on gly-caemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830.
9. Deacon C.F., Nauck M.A., Toft-Nielsen M. et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-1131.
10. Augeri D.J., Robl J.A., Betebenner D.A. et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipepti-dyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:5025-5037.
11. Henry R., Smith S., Schwartz S. et al. p-Cell stimulation by saxagliptin in patients with T2D [abstract no. 447-P plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association. New Orleans 2009.
12. Boulton D.W., Geraldes M. Safety, tolerabilty, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects [abstract no. 606-P plus poster]. 67th Scientific Sessions of the American Diabetes Association. Chicago 2007.
13. Kirby M.S., Dorso C., Wang A. et al. In vitro enzy-mologic characteristics of saxagliptin, a highly potent and selective DPP4 inhibitor with "slow binding" characteristic [abstract]. Clin Chem Lab Med 2008;46:A29.
14. Patel C.G., Li L., Komoroski B.J. et al. No effect ofsaxagliptin on QTc interval in healthy subjects [abstract no. 2072-PO]. 69th Annual Scientific Sessions of the American Diabetes Association. New Orleans 2009.
15. Fura A., Khanna A., Vyas V. et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dis 2009;37:6:1164-1171.
16. Boulton D., Tang A., Patel C. et al. Pharmacokinetics of dipeptidyl pepetidase-4 inhibitor saxagliptin in subjects with renal impairment [abstract no. P357]. 11th European Congress of Endocrinology. Istanbul 2009.
17. Patel C., Castaneda L., Frevert U. et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects [abstract no. 537-P]. Diabetes 2008;57:Suppl 1:A160.
18. Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:5:376-386.
19. Rosenstock J., Aguilar-Salinas C., Klein E. et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:10:2401-2411.
20. DeFronzo R.A., Hissa M.N., Garber A.J. et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabet Care 2009;32:9:1649-1655.
21. Defronzo R.A., Hissa M.N., Garber A.J. et al. Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with T2D [abstract no. 547-P]. 69th Annual Scientific Sessions ofthe American Diabetes Association. New Orleans 2009.
22. Jadzinsky M., Pfutzner A., Paz-Pacheco E. et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:6:611-622.
23. Chacra A.R., Tan G.H., Apanovitch A. et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonyl-urea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:9:1395-1406.
24. Hollander P., Allen E., Li J., Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes [abstract]. Diabetologia 2008;51: Suppl 1:S342.
25. Wolf R., Frederich R., Fiedorek F. et al. Evaluation of CV risk in saxagliptin clinical trials [abstract no. 8-LB plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association. New Orleans 2009.
Рецензия
Для цитирования:
, Расширение группы препаратов, основанных на действии инкретинов: новый ингибитор ДПП-4 саксаглиптин. Проблемы Эндокринологии. 2010;56(5):52-60.
For citation:
Shestakova M.V., Sukhareva O.I. Extension of the group of incretin-targeted preparations: Saxagliptin – a new dipeptidyl peptidase-4 inhibitor. Problems of Endocrinology. 2010;56(5):52-60.
Послать статью по эл. почте 
.jpg){kind=logo}
